Focus Partners Advisor Solutions LLC Raises Position in Intuitive Surgical, Inc. $ISRG

Key Points

• Focus Partners Advisor Solutions LLC increased its stake in Intuitive Surgical, Inc. by 75.8%, holding 3,777 shares valued at approximately $1.87 million as of the end of the first quarter.
• Insiders at Intuitive Surgical have sold a combined 44,769 shares worth over $21 million in recent months, with significant sales from SVP Mark Brosius and insider Gary S. Guthart.
• Intuitive Surgical's earnings report exceeded expectations, with $2.19 EPS compared to an estimate of $1.93, and revenue increased by 21.4% year-over-year, reaching $2.44 billion.

Focus Partners Advisor Solutions LLC increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 75.8% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 3,777 shares of the medical equipment provider's stock after acquiring an additional 1,629 shares during the period. Focus Partners Advisor Solutions LLC's holdings in Intuitive Surgical were worth $1,871,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Chilton Capital Management LLC boosted its stake in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 43 shares during the last quarter. Global Financial Private Client LLC raised its holdings in Intuitive Surgical by 253.3% in the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 38 shares in the last quarter. Elite Financial Inc. acquired a new stake in Intuitive Surgical in the first quarter valued at $26,000. LFA Lugano Financial Advisors SA bought a new position in Intuitive Surgical during the 1st quarter valued at $30,000. Finally, TD Capital Management LLC grew its holdings in Intuitive Surgical by 300.0% during the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock worth $30,000 after acquiring an additional 45 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Insider Activity

In other news, SVP Mark Brosius sold 216 shares of the company's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the sale, the senior vice president directly owned 907 shares of the company's stock, valued at $510,740.77. This represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gary S. Guthart sold 29,360 shares of the company's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the sale, the insider directly owned 19,827 shares of the company's stock, valued at $9,368,059.23. This represents a 59.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,769 shares of company stock worth $21,532,536. 0.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ISRG shares. Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Intuitive Surgical in a research report on Friday, August 22nd. Wall Street Zen upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Truist Financial boosted their price target on Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. BTIG Research raised their price objective on Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $615.00 target price on shares of Intuitive Surgical in a research note on Tuesday, August 19th. Thirteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $595.95.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $469.07 on Wednesday. The firm has a market capitalization of $168.15 billion, a P/E ratio of 65.42, a P/E/G ratio of 4.96 and a beta of 1.61. The business has a 50 day simple moving average of $498.54 and a 200 day simple moving average of $515.81. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The firm had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. During the same period in the previous year, the business posted $1.78 EPS. Intuitive Surgical's revenue was up 21.4% on a year-over-year basis. Research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.